Impala Nordic comments on OncoZenge AB (publ) year-end report. The report positions the case firmly around the upcoming pivotal Phase III study. With the Clinical Trial Application (CTA) submitted in December 2025, the Company expects an approval decision in the second half of April or early May and reiterates its ambition to dose the first patient in Q2 2026.

We see very solid groundwork ahead of the start-up phase, with key partners in place, strengthened clinical leadership, and financing secured to take the Company through the CTA decision window, which puts the spotlight on a clean CTA outcome, recruitment traction, and ultimately the Phase III results.

Click here to read the full comment.